Innovative Drug Shows Promise in Enhancing Cancer Treatment Effectiveness
Smart drug that strips cancer cells of ‘invisibility cloak’ can shrink tumours by 30%, trial shows
Theguardian
Image: Theguardian
A new drug, GRWD5769, developed by researchers in Oxford, has demonstrated the ability to shrink tumors by at least 30% in patients with various cancers. This drug works by making cancer cells visible to the immune system, enhancing the effectiveness of immunotherapy treatments. Early trial results show significant promise, with ongoing studies planned.
- 01GRWD5769 was tested on 83 patients with cervical, bladder, liver, bowel, lung, and head and neck cancers.
- 02The drug led to tumor shrinkage in 26 patients, with 15 experiencing reductions of at least 30%.
- 0318% of cervical cancer patients and 55% of lung cancer patients showed halted disease progression for at least six months.
- 04The drug inhibits an enzyme called ERAP1, which allows cancer cells to hide from T-cells, making them visible for immune attack.
- 05The trial's principal investigator, Prof Fiona Thistlethwaite, emphasized the drug's impressive early results and potential for broader application.
Advertisement
In-Article Ad
Researchers from Oxford have developed a promising new drug, GRWD5769, which has shown the ability to shrink tumors by at least 30% in early trials involving patients with six common cancer types. The drug works by removing the 'invisibility cloak' that cancer cells use to evade the immune system, allowing immunotherapy treatments, specifically cemiplimab, to effectively target and destroy these cells. In a clinical trial across the UK, France, Spain, and Australia, 83 patients who had previously failed other treatments were administered GRWD5769 alongside immunotherapy. Results revealed that tumors shrank in 26 patients, with significant reductions observed in various cancer types. The drug halted disease progression for at least six months in a notable percentage of patients across different cancers. The findings were presented at the American Society of Clinical Oncology's annual meeting, highlighting the potential of GRWD5769 to enhance immunotherapy effectiveness. As the trial continues, researchers express optimism about the drug's future applications in cancer treatment.
Advertisement
In-Article Ad
The development of GRWD5769 could significantly improve treatment outcomes for patients with hard-to-treat cancers, potentially expanding the effectiveness of immunotherapy.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of new cancer treatments like GRWD5769?
Connecting to poll...
Read the original article
Visit the source for the complete story.